SGMT Insider Trading

Insider Ownership Percentage: 17.60%
Insider Buying (Last 12 Months): $1,295,153.50
Insider Selling (Last 12 Months): $0.00

Sagimet Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Sagimet Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sagimet Biosciences Share Price & Price History

Current Price: $4.32
Price Change: Price Decrease of -0.13 (-2.92%)
As of 05/3/2024 01:00 AM ET

This chart shows the closing price history over time for SGMT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Sagimet Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2024David HappelCEOBuy12,100$5.27$63,767.00639,200View SEC Filing Icon  
11/16/2023David HappelCEOBuy590$2.35$1,386.50590View SEC Filing Icon  
7/18/2023Beth C SeidenbergDirectorBuy46,875$16.00$750,000.0046,875View SEC Filing Icon  
7/18/2023Enterprise Associates 13 L NewMajor ShareholderBuy30,000$16.00$480,000.003,850,275View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Sagimet Biosciences (NASDAQ:SGMT)

87.86% of Sagimet Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SGMT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Sagimet Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2024Platinum Investment Management Ltd.111,752$0.61M0.0%-70.9%0.523%Search for SEC Filing on Google Icon
2/5/2024Victory Capital Management Inc.56,570$0.31M0.0%+215.0%0.265%Search for SEC Filing on Google Icon
1/31/2024Federated Hermes Inc.97,276$0.53M0.0%+24.7%0.455%Search for SEC Filing on Google Icon
11/15/2023RTW Investments LP400,277$3.52M0.1%N/A1.875%Search for SEC Filing on Google Icon
11/15/2023Rock Springs Capital Management LP738,355$6.50M0.2%N/A3.458%Search for SEC Filing on Google Icon
11/14/2023Dumac Inc.204,123$1.80M4.8%N/A0.956%Search for SEC Filing on Google Icon
11/13/2023CHI Advisors LLC348,842$3.07M0.9%N/A1.634%Search for SEC Filing on Google Icon
11/13/2023Federated Hermes Inc.78,000$0.69M0.0%N/A0.365%Search for SEC Filing on Google Icon
11/13/2023Silverarc Capital Management LLC100,000$0.88M0.3%N/A0.468%Search for SEC Filing on Google Icon
11/13/2023FMR LLC2,672,355$23.52M0.0%N/A12.517%Search for SEC Filing on Google Icon
11/7/2023New York State Common Retirement Fund6,357$56K0.0%N/A0.030%Search for SEC Filing on Google Icon
11/6/2023Victory Capital Management Inc.17,960$0.16M0.0%N/A0.084%Search for SEC Filing on Google Icon
11/3/2023Platinum Investment Management Ltd.383,913$3.38M0.1%N/A1.798%Search for SEC Filing on Google Icon
10/31/2023Teacher Retirement System of Texas25,000$0.22M0.0%N/A0.117%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sagimet Biosciences logo
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Read More on Sagimet Biosciences

Today's Range

Now: $4.32
Low: $4.25
High: $4.76

50 Day Range

MA: $5.03
Low: $3.90
High: $7.39

52 Week Range

Now: $4.32
Low: $2.13
High: $20.71

Volume

770,646 shs

Average Volume

421,030 shs

Market Capitalization

$137.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Sagimet Biosciences?

Sagimet Biosciences' top insider investors include:
  1. Enterprise Associates 13 L New (Major Shareholder)
  2. David Happel (CEO)
  3. Beth C Seidenberg (Director)
Learn More about top insider investors at Sagimet Biosciences.